Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07791836

Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study

Sponsor: AryoGen Pharmed Co.

View on ClinicalTrials.gov

Summary

This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).

Official title: A Cross-sectional, Observational, Multi-center Study to Assess the Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight (rFVIII-Fc, Manufactured by AryoGen Pharmed Co.)

Key Details

Gender

MALE

Age Range

2 Years - Any

Study Type

OBSERVATIONAL

Enrollment

262

Start Date

2026-08-23

Completion Date

2027-02-20

Last Updated

2026-08-28

Healthy Volunteers

Not specified

Interventions

DRUG

efmoroctocog alfa

This study assesses patients with a history of at least 10 exposure days (EDs) to recombinant factor VIII with Fc fusion (Coageight) within the 12 months prior to enrollment.

Locations (6)

Shahid Baqaei 2 Hospital

Ahvāz, Ahvaz, Iran

Seyyed al-Shohada Hospital

Isfahan, Isfahan, Iran

Soroor Clinic

Mashhad, Mashhad, Iran

Shahid Ayatollah Dastgheib Hospital

Shiraz, Shiraz, Iran

Imam Khomeini Hospital

Tehran, Tehran Province, Iran

Mofid Children's Hospital

Tehran, Tehran Province, Iran